[2021.1] Pharmasaga Founding

Pharmasaga was established in January 2021 as a spin-off startup company from Academia Sinica.

The Company's core technology is derived from the exclusive licensing of PS1, the result of over ten years of research by Academia Sinica's Dr. Wen-Ching Yang's lab.

PS1 is a small-molecule inhibitor of the PDIA4 protein, which plays a critical role in the progression of diabetes. Mouse data indicates that inhibiting PDIA4 with PS1 can prevent pancreatic $\beta$-cell death, stabilize blood glucose and glycated hemoglobin (HbA1c), reduce oxidative stress in $\beta$-cells, and even reverse diabetes.